DNLI_OUT_1 [2025-04-02 14:10:42 -0400] 2251 Bytes | 633 tokens | Cum: 633 tkns (7.91% of 8k)
==========================================================================

Listen up, partner—it's 2:10:41 PM on Wed Apr 02, 2025 -0400, and I’m revved up about Denali Therapeutics (DNLI), climbing from 12.29 to 14.5. This stock is buzzing big-time—do we have a hidden gem, or a flash in the pan? Help me sift through the data!

--- COMPANY PROFILE ---
Company: Denali Therapeutics (DNLI)
IPO: IPO date unknown
Shares Outstanding: 145,220,000
Industry: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Exchange: XNAS

Here's the first list of news for Denali Therapeutics:

C1 - Today 08:00AM - Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program
C2 - Mar-28-25 09:00AM - RNA Biotechs: Current State And Outlook
C3 - Mar-20-25 02:16PM - Denali Therapeutics: Vast Pipeline, First Approval Up Ahead
C4 - Mar-20-25 02:16PM 08:57AM - Why You Shouldn't Bet Against Denali (DNLI) Stock
C5 - Mar-04-25 08:00AM - Denali Therapeutics price target lowered to $42 from $50 at Oppenheimer
C6 - Mar-03-25 12:49PM - Is Denali Therapeutics Inc. (DNLI) Among Jeff Bezos Investments in 2025?
C7 - Feb-27-25 04:01PM - Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
C8 - Feb-06-25 11:42AM - Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Denali Therapeutics (DNLI)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

DNLI_OUT_3 [2025-04-02 14:10:43 -0400] 1101 Bytes | 330 tokens | Cum: 965 tkns (12.06% of 8k)
==========================================================================

Showing C1 (chunk 1 of 11): C1:
**Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program**
Date: Today 08:00AM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/04/02/3054211/0/en/Denali-Therapeutics-Announces-Initiation-of-BLA-Filing-for-Accelerated-Approval-of-Tividenofusp-Alfa-for-the-Treatment-of-Hunter-Syndrome-MPS-II-and-Positive-Ongoing-Interactions-w.html

April 02, 2025 08:00 ET| Source:Denali Therapeutics Inc.Denali Therapeutics Inc.

SOUTH SAN FRANCISCO, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), today announced that the company’s initiation of a rolling submission of a biologics license application (BLA) for accelerated approval of tividenofusp alfa for the treatment of

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

DNLI_OUT_5 [2025-04-02 14:10:44 -0400] 1014 Bytes | 306 tokens | Cum: 1273 tkns (15.91% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-02T08:11:49Z - Denali Therapeutics (NASDAQ:DNLI) Sets New 12-Month Low - Should You Sell?...
A2 - 2025-04-02T12:00:00Z - Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa...
A3 - 2025-04-02T12:12:57Z - Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa...
A4 - 2025-04-02T12:29:09Z - Denali Therapeutics (DNLI) Announces Initiation of BLA Filing for Accelerated Approval of Tividenofu...
A5 - 2025-04-02T12:00:44Z - Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

DNLI_OUT_7 [2025-04-02 14:10:48 -0400] 1098 Bytes | 320 tokens | Cum: 1595 tkns (19.94% of 8k)
==========================================================================

Showing A1 (chunk 1 of 8): A1:
**Denali Therapeutics (NASDAQ:DNLI) Sets New 12-Month Low - Should You Sell?**Date: 2025-04-02Source: {'uri': 'marketbeat.com', 'dataType': 'news', 'title': 'Market Beat'}URL: https://www.marketbeat.com/instant-alerts/denali-therapeutics-nasdaqdnli-sets-new-12-month-low-should-you-sell-2025-04-01/Denali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report)'s share price hit a new 52-week low during mid-day trading on Tuesday . The stock traded as low as $13.30 and last traded at $13.60, with a volume of 3555583 shares changing hands. The stock had previously closed at $14.78.

A number of equities analysts have recently issued reports on the stock. Bank of America dropped their price objective on shares of Denali Therapeutics from $30.00 to $28.00 and set a "buy" rating for the company in a research note on Monday, March 10th. The Goldman Sachs Group cut their price target on shares of

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

DNLI_OUT_9 [2025-04-02 14:10:49 -0400] 1251 Bytes | 367 tokens | Cum: 2059 tkns (25.74% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-04-02T12:00:00Z - Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program
B2 - 2025-02-18T18:00:00Z - Mucopolysaccharidosis Market Analysis Across 7MM — Unveiling Growth Opportunities Across Different Types | DelveInsight
B3 - 2025-02-13T18:00:00Z - Alpha-Synuclein Inhibitors Clinical Trial Pipeline as Novel and Extensive 22+ Therapies Likely to Enter in the Domain | DelveInsight
B4 - 2025-02-11T08:48:00Z - Neuroregeneration Therapy Market to Surpass USD 64.8 Billion by 2034, Driven by Advancements in Regenerative Medicine and Rising Neurological Disorders | Transparency Market Research
B5 - 2024-08-01T16:25:00Z - Biogen (BIIB) Q2 Earnings & Sales Beat, 2024 Guidance Raised
B6 - 2024-07-04T01:40:57Z - Denali Therapeutics director sells over $678k in company stock By Investing.com - Investing.com

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

DNLI_OUT_11 [2025-04-02 14:10:52 -0400] 1076 Bytes | 293 tokens | Cum: 2354 tkns (29.43% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/04/02/3054211/0/en/Denali-Therapeutics-Announces-Initiation-of-BLA-Filing-for-Accelerated-Approval-of-Tividenofusp-Alfa-for-the-Treatment-of-Hunter-Syndrome-MPS-II-and-Positive-Ongoing-Interactions-w.htmlDenali Therapeutics has initiated a rolling submission of a biologics license application (BLA) for accelerated approval of tividenofusp alfa for the treatment of Hunter syndrome (MPS II). The company also has positive ongoing interactions with the FDA on the development of DNL126 for Sanfilippo syndrome type A (MPS IIIA) through the START program.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

DNLI_OUT_13 [2025-04-02 14:10:53 -0400] 1143 Bytes | 310 tokens | Cum: 2739 tkns (34.24% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-04-02 8-K Item 7.01 Regulation FD Disclosure.

On April 2, 2025, Denali Therapeutics Inc. issued a press release announcing it has initiated a rolling submission of a biologics license application for accelerated approval of tividenofusp alfa for the treatment of Hunter syndrome (MPS II)....

S2 - 2025-03-05 8-K Item 7.01 Regulation FD Disclosure.

On March 5, 2025, Denali Therapeutics Inc. provided an update that further analyses from Regimen G of the Phase 2/3 HEALEY ALS Platform Trial evaluating eIF2B agonist DNL343 in the treatment of amyotrophic lateral sclerosis (ALS) did not demo...

S3 - 2025-02-27 8-K Item 1.01 Entry into a Material Definitive Agrmt.

On February 27, 2025, Denali Therapeutics Inc. (the Company) entered into an equity distribution agreement (the Agrmt) with Goldman Sachs Co. LLC (Goldman) and Leerink Partners LLC (Leerink Partners), pursuant to which t...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

DNLI_OUT_15 [2025-04-02 14:11:00 -0400] 1073 Bytes | 270 tokens | Cum: 3011 tkns (37.64% of 8k)
==========================================================================

Showing S1 (chunk 1 of 1): S1:
Item 7.01 Regulation FD Disclosure.

On April 2, 2025, Denali Therapeutics Inc. issued a press release announcing it has initiated a rolling submission of a biologics license application for accelerated approval of tividenofusp alfa for the treatment of Hunter syndrome (MPS II).

A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

The information furnished in this Item 7.01 and Item 9.01 (including Exhibit 99.1) shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing....

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

DNLI_OUT_17 [2025-04-02 14:11:09 -0400] 6434 Bytes | 1773 tokens | Cum: 4916 tkns (61.45% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+-------------------+-----------------------+-------------------------+--------------------------+
| Volume: 1,919,936 | Perf Month: -8.41% | Option/Short: Yes / Yes | Sales Y/Y TTM: -100.00% |
+-------------------+-----------------------+-------------------------+--------------------------+
| Avg Volume: 1.15M | Perf Quarter: -27.82% | Short Float: 8.36% | ROE: -37.40% |
+-------------------+-----------------------+-------------------------+--------------------------+
| Rel Volume: 2.40 | Index: RUT | Short Ratio: 9.12 | ROI: -33.24% |
+-------------------+-----------------------+-------------------------+--------------------------+
| RSI (14): 44.58 | Market Cap: 2.12B | Short Interest: 10.51M | Sales Surprise: -100.00% |
+-------------------+-----------------------+-------------------------+--------------------------+
| ATR (14): 1.17 | Shs Outstand: 142.63M | Beta: 1.53 | EPS Surprise: 16.12% |
+-------------------+-----------------------+-------------------------+--------------------------+
| SMA20: -0.93% | Shs Float: 125.71M | Sales Q/Q: - | P/E: - |
+-------------------+-----------------------+-------------------------+--------------------------+
| SMA50: -21.17% | Inst Own: 88.04% | Sales past 5Y: 260.06% | Earnings: Feb 27 AMC |
+-------------------+-----------------------+-------------------------+--------------------------+
| SMA200: -36.77% | Insider Own: 13.43% | Employees: 422 | |
+-------------------+-----------------------+-------------------------+--------------------------+
| Perf Week: 5.78% | Insider Trans: -1.13% | Debt/Eq: 0.04 | |
+-------------------+-----------------------+-------------------------+--------------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

Inside Trans: Denali Therapeutics Inc. (DNLI) by Krognes Steve E. (Unknown Title) on 2025-01-07
- Common Stock: 3339 shares at $20.81 (D) Footnote: Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units.

Inside Trans: Denali Therapeutics Inc. (DNLI) by Watts Ryan J. (President and CEO) on 2025-01-06
- Common Stock: 29266 shares at $20.22 (D) Footnote: Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units.
- Common Stock: 7650 shares at $20.81 (D) Footnote: Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units.

Inside Trans: Denali Therapeutics Inc. (DNLI) by Schuth Alexander O. (COFO and Secretary) on 2025-01-06
- Common Stock: 12255 shares at $20.22 (D) Footnote: Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units.
- Common Stock: 2907 shares at $20.81 (D) Footnote: Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units.

Inside Trans: Denali Therapeutics Inc. (DNLI) by Ho Carole (Chief Medical Officer) on 2025-01-06
- Common Stock: 12255 shares at $20.22 (D) Footnote: Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units.
- Common Stock: 2907 shares at $20.81 (D) Footnote: Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units.

Inside Trans: Denali Therapeutics Inc. (DNLI) by Ho Carole (Chief Medical Officer) on 2025-01-03
- Common Stock: 54180 shares at $0 (D)
- Stock Option (right to buy): 162540 shares at $0 (D)

Inside Trans: Denali Therapeutics Inc. (DNLI) by Schuth Alexander O. (COFO and Secretary) on 2025-01-03
- Common Stock: 54180 shares at $0 (D)
- Stock Option (right to buy): 162540 shares at $0 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 14537000.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -427493000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 14.25
Average Volume: 1490468.39
30-Day High: 16.69
30-Day Low: 12.29

[Detailed Financials: Q3 2024]
- Total Assets: $1,454,013,000.0
- Total Liabilities: $135,518,000.0
- Total Equity: $1,318,495,000.0
- Current Assets: $868,839,000.0
- Current Liabilities: $87,093,000.0

[Income Statement: Q3 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.63

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $15,957,000.0

[Detailed Financials: Q2 2024]
- Total Assets: $1,502,565,000.0
- Total Liabilities: $115,514,000.0
- Total Equity: $1,387,051,000.0
- Current Assets: $928,383,000.0
- Current Liabilities: $74,533,000.0

[Income Statement: Q2 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.59

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $14,105,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

DNLI_OUT_19 [2025-04-02 14:11:13 -0400] 676 Bytes | 167 tokens | Cum: 5324 tkns (66.55% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

DNLI_IN_21 [2025-04-02 14:11:14 -0400] 126 Bytes | 29 tokens | Cum: 5419 tkns (67.74% of 8k)
==========================================================================

====================================
[2025-04-02 14:11:14] # Analysis Completed
Elapsed Time: 32.54 seconds